Literature DB >> 21510778

Cytokine secretion pattern in treatment of lymphocytes of multiple sclerosis patients with fumaric acid esters.

Samaneh Zoghi1, Zahra Amirghofran, Alireza Nikseresht, Nahid Ashjazadeh, Eskandar Kamali-Sarvestani, Nahid Rezaei.   

Abstract

The present study was performed to investigate the effects of dimethylfumarate (DMF) and methylhydrogen fumarate (MHF) on the cytokine pattern of peripheral blood mononuclear cells (PBMCs) of multiple sclerosis (MS) patients. The PBMCs from patients and healthy controls were stimulated with myelin basic protein (MBP) or phytohemagglutinin (PHA) and cultured in the presence of DMF and MHF. The percentage of CD4+IL-4+ and CD4+IFN-γ+ cells was determined by means of intracellular cytokine staining. CD4+IL-4+ cells were significantly increased in the presence of DMF and MHF when PBMCs were stimulated by MBP (P < 0.003). The same significant result was obtained by PHA stimulation (P < 0.049). In terms of CD4+IFN-γ+ cells, the percentage of cells did not significantly differ between the cultures stimulated with MBP or PHA in the presence and absence of the drugs. Results of MBP stimulation in control group also showed a significant increase in CD4+IL-4+ cells in the presence of DMF and MHF. In comparison between patient and control groups, no statistically significant changes were observed. In conclusion, both DMF and MHF effectively increased IL-4 production, whereas they did not significantly change IFN-γ level, indicating the role of these drugs in increasing the production of beneficial cytokines such as IL-4.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21510778     DOI: 10.3109/08820139.2011.569626

Source DB:  PubMed          Journal:  Immunol Invest        ISSN: 0882-0139            Impact factor:   3.657


  8 in total

1.  Elevated IL-38 Serum Levels in Newly Diagnosed Multiple Sclerosis and Systemic Sclerosis Patients.

Authors:  Maryam Zarrabi; Mohammadali Nazarinia; Abbas Rahimi Jaberi; Nasser Gholijani; Zahra Amirghofran
Journal:  Med Princ Pract       Date:  2020-10-20       Impact factor: 1.927

Review 2.  Immunopathology of multiple sclerosis.

Authors:  Calliope A Dendrou; Lars Fugger; Manuel A Friese
Journal:  Nat Rev Immunol       Date:  2015-08-07       Impact factor: 53.106

Review 3.  Dimethyl fumarate modulation of immune and antioxidant responses: application to HIV therapy.

Authors:  Alexander J Gill; Dennis L Kolson
Journal:  Crit Rev Immunol       Date:  2013       Impact factor: 2.214

4.  Coenzyme Q10 supplementation reduces peripheral oxidative stress and inflammation in interferon-β1a-treated multiple sclerosis.

Authors:  Marcello Moccia; Antonio Capacchione; Roberta Lanzillo; Fortunata Carbone; Teresa Micillo; Francesco Perna; Anna De Rosa; Antonio Carotenuto; Roberto Albero; Giuseppe Matarese; Raffaele Palladino; Vincenzo Brescia Morra
Journal:  Ther Adv Neurol Disord       Date:  2019-02-18       Impact factor: 6.570

5.  Modulation of in vitro proliferation and cytokine secretion of human lymphocytes by Mentha longifolia extracts.

Authors:  Yahya Asemani; Maryam BayaT; Saeed Malek-Hosseini; Zahra Amirghofran
Journal:  Avicenna J Phytomed       Date:  2019 Jan-Feb

6.  Dimethyl fumarate treatment alters circulating T helper cell subsets in multiple sclerosis.

Authors:  Catharina C Gross; Andreas Schulte-Mecklenbeck; Svenja Klinsing; Anita Posevitz-Fejfár; Heinz Wiendl; Luisa Klotz
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2015-12-10

Review 7.  Dimethyl fumarate in the management of multiple sclerosis: appropriate patient selection and special considerations.

Authors:  Luca Prosperini; Simona Pontecorvo
Journal:  Ther Clin Risk Manag       Date:  2016-03-02       Impact factor: 2.423

8.  Presenilin1 regulates Th1 and Th17 effector responses but is not required for experimental autoimmune encephalomyelitis.

Authors:  Matthew Cummings; Anitha Christy Sigamani Arumanayagam; Picheng Zhao; Sunil Kannanganat; Olaf Stuve; Nitin J Karandikar; Todd N Eagar
Journal:  PLoS One       Date:  2018-08-08       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.